2019-20 ASCO President Howard Burris III commends CMS for reflecting recommendations in the Society’s position statement on pharmacy benefit managers in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.
The emergence of novel systemic therapies — combined in new and better ways — has significantly changed the role of cancer surgery. In recognition of the substantial progress made in this area in the past year, in Clinical Cancer Advances 2020 — just released today— the American Society of Clinical Oncology (ASCO) has named is the Refinement of Surgical Treatment of Cancer as the Advance of the Year.
The American Society of Clinical Oncology released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid—or block grants—could have on patients with cancer.
Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25, 2020 at the Moscone West Building in San Francisco, California.
Statement by ASCO President Howard A. "Skip" Burris III, MD, FACP, FASCO, applauding the Surgeon General for releasing its first report on smoking cessation in 30 years.
A retrospective analysis of 26,768 young adults age 40 and under found that those who live in areas with lower income (less than $38,000) and lower education (under 79% high school graduation rate), as well as those who live in urban areas, had worse outcomes and a higher risk of death.
Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer and unresectable hepatocellular carcinoma.
ASCO applauds Congress for working across party lines to raise the minimum age for purchasing tobacco products to 21 and for continuing its commitment to investing in our nation's biomedical research infrastructure.
Nine oncology practices from rural and urban centers in the U.S. that primarily treat underserved populations have received grant funding to participate in the American Society of Clinical Oncology’s (ASCO) Quality Oncology Practice Initiative (QOPI®) and Quality Training Program. ASCO announced today the recipients of the grants, which are supported by the Stavros Niarchos Foundation.
The American Society of Clinical Oncology (ASCO) has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2021.
ASCO President Howard "Skip" Burris congratulates Dr. Stephen Hahn on his confirmation to serve as Commissioner of the U.S. FDA.
On November 26, 2019, ASCO released a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality, high-value care.
Two science-based organizations—CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives—are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.
Twenty-Four practices in two countries elevated their standard of care and achieved the American Society of Clinical Oncology's (ASCO) Quality Oncology Practice Initiative (QOPI®) Certification in the third quarter of this year.
Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer through a collaboration between the International Association for the Study of Lung Cancer (IASLC) and ASCO.